<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250207213747&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20250207213747&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 08 Feb 2025 02:37:48 +0000</lastbuilddate>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>New light shed on sex-related risk factors and frailty</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7;46(6):493-496. doi: 10.1093/eurheartj/ehae932.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918852/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918852</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae932>10.1093/eurheartj/ehae932</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918852</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New light shed on sex-related risk factors and frailty</dc:title>
<dc:identifier>pmid:39918852</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae932</dc:identifier>
</item>
<item>
<title>Correction to: Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7:ehaf107. doi: 10.1093/eurheartj/ehaf107. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf107>10.1093/eurheartj/ehaf107</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918843</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification</dc:title>
<dc:identifier>pmid:39918843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf107</dc:identifier>
</item>
<item>
<title>Redefining Outcomes in Pediatric Cardiovascular Research: The Promise of Days Alive Out of Health Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(25)00019-1. doi: 10.1016/j.jacc.2024.12.027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918474</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.027>10.1016/j.jacc.2024.12.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918474</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Emily M Bucholz</dc:creator>
<dc:creator>John M Costello</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Redefining Outcomes in Pediatric Cardiovascular Research: The Promise of Days Alive Out of Health Care</dc:title>
<dc:identifier>pmid:39918474</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.027</dc:identifier>
</item>
<item>
<title>Setting Benchmarks for Long-Term Success of Surgical Mitral Valve Repair in Reference Centers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 25:S0735-1097(24)10484-6. doi: 10.1016/j.jacc.2024.11.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918473</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.018>10.1016/j.jacc.2024.11.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918473</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Makoto Mori</dc:creator>
<dc:creator>Arnar Geirsson</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Setting Benchmarks for Long-Term Success of Surgical Mitral Valve Repair in Reference Centers</dc:title>
<dc:identifier>pmid:39918473</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.018</dc:identifier>
</item>
<item>
<title>Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 22:S0735-1097(24)10659-6. doi: 10.1016/j.jacc.2024.11.049. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918472</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.049>10.1016/j.jacc.2024.11.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918472</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Stefano Masi</dc:creator>
<dc:creator>Hermann Dalpiaz</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39918472</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.049</dc:identifier>
</item>
<item>
<title>Incorporating the Totality of Ischemic and Hemorrhagic Events: The Case of the AUGUSTUS Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 20:S0735-1097(24)10614-6. doi: 10.1016/j.jacc.2024.11.047. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918471</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.047>10.1016/j.jacc.2024.11.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918471</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Incorporating the Totality of Ischemic and Hemorrhagic Events: The Case of the AUGUSTUS Trial</dc:title>
<dc:identifier>pmid:39918471</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.047</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes of Contemporary Surgical Repair for Degenerative Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This contemporary series provides further data on the low in-hospital mortality and excellent long-term outcomes of surgical mitral repair when performed in a high-volume center. Preoperative symptoms are associated with worse outcomes. Isolated anterior leaflet disease increases the risk of reoperation, heart failure rehospitalization, and late mortality compared to posterior or bileaflets pathology.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 16:S0735-1097(24)10356-7. doi: 10.1016/j.jacc.2024.10.108. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There are limited published reports about the long-term outcomes of contemporary surgical mitral repair series for degenerative mitral regurgitation performed at a high-volume center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study is to report independently adjudicated long-term results of contemporary mitral repair surgery performed at a high-volume center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective study was conducted on 3,317 patients who underwent surgical mitral repair for degenerative mitral regurgitation at a tertiary care center between January 1, 2008 and December 31, 2017. Follow-up data, focusing on survival, reinterventions, and heart failure rehospitalizations were adjudicated and analyzed by the Italian National Agency for Regional Healthcare Services. Echocardiographic assessments during follow-up were not included. Complete (100%) data linkage was achieved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median age of the patients was 57 years, and 68.56% were men. The overall in-hospital mortality was 0.48% (16 of 3,317) for all cases and 0.21% (5 of 2,399) in isolated mitral valve repair. The 10-year survival was 89.65% (95% CI: 88.75%-90.55%), independently associated with preoperative symptoms and anterior leaflet disease. Freedom from reoperation was 96.63% (95% CI: 95.63%-97.63%) at 10 years. Anterior leaflet disease, a second run of cardiopulmonary bypass, and more than mild mitral regurgitation at discharge were associated with increased risk of reoperation. Finally, 10-year freedom from rehospitalization for heart failure was 92.24% (95% CI: 90.62%-93.86%), with age, prior hospitalization for heart failure, preoperative symptoms, and anterior leaflet disease identified as independent risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This contemporary series provides further data on the low in-hospital mortality and excellent long-term outcomes of surgical mitral repair when performed in a high-volume center. Preoperative symptoms are associated with worse outcomes. Isolated anterior leaflet disease increases the risk of reoperation, heart failure rehospitalization, and late mortality compared to posterior or bileaflets pathology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918470</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.108>10.1016/j.jacc.2024.10.108</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918470</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Benedetto Del Forno</dc:creator>
<dc:creator>Guido Ascione</dc:creator>
<dc:creator>Davide Carino</dc:creator>
<dc:creator>Mariangela D'Ovidio</dc:creator>
<dc:creator>Elisabetta Lapenna</dc:creator>
<dc:creator>Alessandro Verzini</dc:creator>
<dc:creator>Paolo Denti</dc:creator>
<dc:creator>Andrea Blasio</dc:creator>
<dc:creator>Nicolò Azzola Guicciardi</dc:creator>
<dc:creator>Anna Mara Scandroglio</dc:creator>
<dc:creator>Fabrizio Monaco</dc:creator>
<dc:creator>Eustachio Agricola</dc:creator>
<dc:creator>Marina Davoli</dc:creator>
<dc:creator>Giorgia Duranti</dc:creator>
<dc:creator>Giovanni Baglio</dc:creator>
<dc:creator>Enrico Coscioni</dc:creator>
<dc:creator>Alessandro Castiglioni</dc:creator>
<dc:creator>Ottavio Alfieri</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcomes of Contemporary Surgical Repair for Degenerative Mitral Regurgitation</dc:title>
<dc:identifier>pmid:39918470</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.108</dc:identifier>
</item>
<item>
<title>Days Alive Out of Health Care: A Novel Measure of Health Status After Congenital Heart Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this data set of children with Medicaid coverage, total DAoH is an easily reproducible, patient-centered outcome that should be considered for assessment of longitudinal outcomes for neonates and infants undergoing cardiac surgery. Where outpatient data are not available, days alive and out of hospital might serve as a reasonable alternative.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 28:S0735-1097(24)10561-X. doi: 10.1016/j.jacc.2024.11.046. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: As pediatric and adult operative mortality improves, longitudinal outcomes beyond survival become increasingly important. "Days alive and out of hospital" is well-studied as a longitudinal, patient-centered outcome in adult populations. However, it has yet to be validated for children, whose health care use and survival differ from that of adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate days alive and out of health care/hospital as outcomes for neonatal and infant cardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using linked, locally held, clinical registry data, the National Death Index, and Medicaid claims from the CHS-COLOUR (New York Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources), we describe and compare the distribution of days alive and out of health care/hospital (730 days or date of death minus date of birth, minus the sum of days in health care) over 2 years for New York State Medicaid-enrolled children who underwent initial neonatal or infant cardiac surgery during 2006 to 2018. We assess relative contributions of mortality, inpatient, and outpatient days, test impacts of alternate outpatient day weightings, and assess associations with patient characteristics known to be associated with other, established congenital heart surgical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 2,519 Medicaid-enrolled neonates/infants underwent initial cardiac surgery in the first year of life across New York state during 2006 to 2018. Days alive and out of health care (DAoH) (0-730 days) was bimodally distributed, with 10.4% (n = 261) spending &lt;100 days and 21.6% (n = 545) spending >;700 DAoH. We found that 5.9% (n = 149) of children died during their birth admission (0 DAoH). Cardiac disease complexity, weight at surgery, noncardiac preoperative comorbidities, and other preoperative risk factors were all significantly associated with the outcomes (P &lt;0.001). When considering only inpatient days, the distribution was more left-skewed, because 40% of health care days in the second year of life was attributable to outpatient days. Our findings were otherwise largely insensitive to health care type weightings.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this data set of children with Medicaid coverage, total DAoH is an easily reproducible, patient-centered outcome that should be considered for assessment of longitudinal outcomes for neonates and infants undergoing cardiac surgery. Where outpatient data are not available, days alive and out of hospital might serve as a reasonable alternative.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918469</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.046>10.1016/j.jacc.2024.11.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918469</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Chantal M Sanchez</dc:creator>
<dc:creator>Kacie Dragan</dc:creator>
<dc:creator>Joyce L Woo</dc:creator>
<dc:creator>Pengfei Jiang</dc:creator>
<dc:creator>Matthew Neidell</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Days Alive Out of Health Care: A Novel Measure of Health Status After Congenital Heart Surgery</dc:title>
<dc:identifier>pmid:39918469</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.046</dc:identifier>
</item>
<item>
<title>Early Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: New Treatment Paradigms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(24)10715-2. doi: 10.1016/j.jacc.2024.12.019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918468</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.019>10.1016/j.jacc.2024.12.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918468</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:creator>Rohin K Reddy</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: New Treatment Paradigms</dc:title>
<dc:identifier>pmid:39918468</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.019</dc:identifier>
</item>
<item>
<title>Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with AF and recent ACS or PCI, apixaban significantly reduced total bleeding risk compared with VKA. Aspirin doubled total bleeding risk compared with placebo without a significant change in total ischemic events. Based on this assessment of total events, our findings support the use of apixaban plus a low-potency P2Y(12) inhibitor (ie, clopidogrel) without aspirin as the standard therapy for this high-risk patient population. (A Study of Apixaban in Patients With...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(24)10555-4. doi: 10.1016/j.jacc.2024.10.125. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited data exist on the optimal antithrombotic strategy to minimize total bleeding and ischemic events for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) and atrial fibrillation (AF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to identify the antithrombotic regimen that minimized total major or clinically relevant nonmajor bleeding events, ischemic events, and hospitalizations after ACS or PCI in AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a secondary analysis of AUGUSTUS (Open-label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), a 2×2 factorial, randomized trial evaluating apixaban vs a vitamin K antagonist (VKA) and aspirin vs placebo in patients with AF and ACS or PCI who were on P2Y<sub>12</sub> inhibitor therapy. We determined the incidence of total major or clinically relevant nonmajor bleeding events in patients receiving at least 1 dose of study therapy, total ischemic events, and total hospitalizations among patients randomized to each antithrombotic strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over 6 months of follow-up, 573 of 4,568 (12.5%) patients experienced at least 1 bleeding event while on study drug; among them, 110 (19.2%) had multiple bleeding events. Compared with those with 1 bleeding event, patients with multiple bleeding events were more likely to be on a high-potency P2Y<sub>12</sub> inhibitor (prasugrel or ticagrelor vs clopidogrel). Of the 4,614 randomized participants, 219 (4.7%) had at least 1 ischemic event, among whom 75 (34.2%) had multiple ischemic events. At least 1 hospitalization occurred in 1,125 (24.4%) patients; among them, 384 (34.1%) had multiple hospitalizations. Apixaban, compared with VKA, significantly reduced the risk of total bleeding (rate ratio [RR]: 0.66; 95% CI: 0.55-0.80). Apixaban had similar rates of total ischemic events (RR: 0.83; 95% CI: 0.58-1.20) and total hospitalizations (RR: 0.90; 95% CI: 0.79-1.03) compared with VKA. Aspirin, compared with placebo, significantly increased the risk of total bleeding (RR: 2.14; 95% CI: 1.75-2.60). The rates of total ischemic events (RR: 0.75; 95% CI: 0.52-1.08) and total hospitalizations (RR: 1.11; 95% CI: 0.97-1.27) with aspirin and placebo were similar.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with AF and recent ACS or PCI, apixaban significantly reduced total bleeding risk compared with VKA. Aspirin doubled total bleeding risk compared with placebo without a significant change in total ischemic events. Based on this assessment of total events, our findings support the use of apixaban plus a low-potency P2Y<sub>12</sub> inhibitor (ie, clopidogrel) without aspirin as the standard therapy for this high-risk patient population. (A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis [Blood Clots] Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart; NCT02415400).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918467</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.125>10.1016/j.jacc.2024.10.125</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918467</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Manasi Tannu</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Ronald Aronson</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS</dc:title>
<dc:identifier>pmid:39918467</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.125</dc:identifier>
</item>
<item>
<title>Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF: Lessons From the SUMMIT CMR Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(24)10665-1. doi: 10.1016/j.jacc.2024.12.013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918466</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.013>10.1016/j.jacc.2024.12.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918466</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Carlos E Rochitte</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF: Lessons From the SUMMIT CMR Substudy</dc:title>
<dc:identifier>pmid:39918466</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.013</dc:identifier>
</item>
<item>
<title>Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39918465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with AF and stable CAD, OAC monotherapy, compared with OAC plus SAPT, was not associated with a statistically significant increased risk of ischemic events but resulted in a significantly reduced risk of bleeding.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 17:S0735-1097(25)00071-3. doi: 10.1016/j.jacc.2024.12.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal long-term antithrombotic strategy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains uncertain. Individual randomized controlled trials (RCTs) had variations in their reported results and were not powered for effectiveness outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to pool the results of RCTs comparing the effectiveness and safety of oral anticoagulation (OAC) monotherapy vs OAC plus single antiplatelet therapy (SAPT) in patients with AF and stable CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We systematically searched PubMed, Embase, and ClinicalTrials.gov until September 09, 2024. The primary effectiveness outcome was a composite of myocardial infarction, ischemic stroke, systemic embolism, or death. The primary safety outcome was major bleeding. We obtained unpublished results from principal investigators of the included RCTs, as needed, to calculate pooled HRs and 95% CIs and to perform prespecified subgroup analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 690 screened records, 4 RCTs with 4,092 randomized patients were included (2 using edoxaban, 1 using rivaroxaban, and 1 using any oral anticoagulant; mean age 73.9 years, 20.1% women). The median follow-up durations ranged from 12 to 30 months (overall estimated weighted mean follow-up of 21.9 months). There were no statistically significant differences between OAC monotherapy vs OAC plus SAPT in the primary effectiveness outcome (7.3% vs 8.2%; HR: 0.90; 95% CI: 0.72-1.12), myocardial infarction (1.0% vs 0.7%; HR: 1.51; 95% CI: 0.75-3.04), ischemic stroke (1.9% vs 2.1%; HR: 0.89; 95% CI: 0.57-1.37), all-cause death (4.2% vs 5.3%; HR: 0.94; 95% CI: 0.49-1.80), or cardiovascular death (2.4% vs 3.0%; HR: 0.79; 95% CI: 0.54-1.15). OAC monotherapy was associated with a lower risk of major bleeding than OAC plus SAPT (3.3% vs 5.7%; HR: 0.59; 95% CI: 0.44-0.79). Subgroup analyses did not show significant interactions for effectiveness but suggested that the magnitude of bleeding reduction may be greater among men (P<sub>interaction</sub> = 0.03) and among patients with diabetes mellitus (P<sub>interaction</sub> = 0.04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with AF and stable CAD, OAC monotherapy, compared with OAC plus SAPT, was not associated with a statistically significant increased risk of ischemic events but resulted in a significantly reduced risk of bleeding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39918465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39918465</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.030>10.1016/j.jacc.2024.12.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39918465</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sina Rashedi</dc:creator>
<dc:creator>Mohammad Keykhaei</dc:creator>
<dc:creator>Alyssa Sato</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Satoshi Yasuda</dc:creator>
<dc:creator>Hisao Ogawa</dc:creator>
<dc:creator>Satoshi Shizuta</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Yasuo Okumura</dc:creator>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Laurent Bertoletti</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials</dc:title>
<dc:identifier>pmid:39918465</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.030</dc:identifier>
</item>
<item>
<title>Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39917842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4^(+) T cells drives type 2 immune responses, resulting in an accumulation of iNKT2 and Th2 cells, memory T cells and anti-inflammatory macrophages that limit the progression of atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 7. doi: 10.1161/CIRCULATIONAHA.124.072384. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The activation and polarization of T cells play a crucial role in atherosclerosis and dictate athero-inflammation. The epigenetic enzyme EZH2 (enhancer of zeste homolog 2) mediates the H3K27me3 (trimethylation of histone H3 lysine 27) and is pivotal in controlling T cell responses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To detail the role of T cell EZH2 in atherosclerosis, we used human carotid endarterectomy specimens to reveal plaque expression and geography of EZH2. Atherosclerosis-prone <i>Apoe</i> (apolipoprotein E)-deficient mice with CD (cluster of differentiation) 4<sup>+</sup> or CD8<sup>+</sup> T cell-specific <i>Ezh2</i> deletion (Ezh2<sup>cd4</sup>-knockout [KO], Ezh2<sup>cd8</sup>-KO) were analyzed to unravel the role of T cell Ezh2 in atherosclerosis and T cell-associated immune status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>EZH2</i> expression is elevated in advanced human atherosclerotic plaques and primarily expressed in the T cell nucleus, suggesting the importance of canonical EZH2 function in atherosclerosis. Ezh2<sup>cd4</sup>-KO, but not Ezh2<sup>cd8</sup>-KO, mice showed reduced atherosclerosis with fewer advanced plaques, which contained less collagen and macrophages, indicating that Ezh2 in CD4<sup>+</sup> T cells drives atherosclerosis. In-depth analysis of CD4<sup>+</sup> T cells of Ezh2<sup>cd4</sup>-KO mice revealed that absence of Ezh2 results in a type 2 immune response with increased Il-4 (interleukin 4) gene and protein expression in the aorta and lymphoid organs. In vitro, <i>Ezh2</i>-deficient T cells polarized macrophages toward an anti-inflammatory phenotype. Single-cell RNA-sequencing of splenic T cells revealed that <i>Ezh2</i> deficiency reduced naive, Ccl5<sup>+</sup> (C-C motif chemokine ligand 5) and regulatory T cell populations and increased the frequencies of memory T cells and invariant natural killer T (iNKT) cells. Flow cytometric analysis identified a shift toward Th2 (type 2 T helper) effector CD4<sup>+</sup> T cells in Ezh2<sup>cd4</sup>-KO mice and confirmed a profound increase in splenic iNKT cells with increased expression of Plzf (promyelocytic leukemia zinc finger), which is the characteristic marker of the iNKT2 subset. Likewise, <i>Zbtb16</i> ([zinc finger and BTB domain containing 16], a Plzf-encoding gene) transcripts were elevated in the aorta of Ezh2<sup>cd4</sup>-KO mice, suggesting an accumulation of iNKT2 cells in the plaque. H3K27me3-chromatin immunoprecipitation followed by quantitative polymerase chain reaction showed that T cell-Ezh2 regulates the transcription of the <i>Il-4</i> and <i>Zbtb16</i> genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4<sup>+</sup> T cells drives type 2 immune responses, resulting in an accumulation of iNKT2 and Th2 cells, memory T cells and anti-inflammatory macrophages that limit the progression of atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39917842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39917842</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072384>10.1161/CIRCULATIONAHA.124.072384</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39917842</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cecilia Assunta Bonfiglio</dc:creator>
<dc:creator>Michael Lacy</dc:creator>
<dc:creator>Vasiliki Triantafyllidou</dc:creator>
<dc:creator>Floriana Maria Farina</dc:creator>
<dc:creator>Aleksandar Janjic</dc:creator>
<dc:creator>Katrin Nitz</dc:creator>
<dc:creator>Yuting Wu</dc:creator>
<dc:creator>Venetia Bazioti</dc:creator>
<dc:creator>Irem Avcilar-Kucukgoze</dc:creator>
<dc:creator>Yonara Freire Soares Marques</dc:creator>
<dc:creator>Markus Joppich</dc:creator>
<dc:creator>Mahadia Kumkum</dc:creator>
<dc:creator>Katja Röß</dc:creator>
<dc:creator>Anuroop Venkateswaran Venkatasubramani</dc:creator>
<dc:creator>Axel Imhof</dc:creator>
<dc:creator>Wolfgang Enard</dc:creator>
<dc:creator>Lars Maegdefessel</dc:creator>
<dc:creator>Menno de Winther</dc:creator>
<dc:creator>Christian Weber</dc:creator>
<dc:creator>Donato Santovito</dc:creator>
<dc:creator>Esther Lutgens</dc:creator>
<dc:creator>Dorothee Atzler</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis</dc:title>
<dc:identifier>pmid:39917842</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072384</dc:identifier>
</item>
<item>
<title>Adverse pregnancy outcomes and cardiovascular disease: family matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39916373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7:ehae905. doi: 10.1093/eurheartj/ehae905. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39916373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39916373</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae905>10.1093/eurheartj/ehae905</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39916373</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Aarti Thakkar</dc:creator>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adverse pregnancy outcomes and cardiovascular disease: family matters</dc:title>
<dc:identifier>pmid:39916373</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae905</dc:identifier>
</item>
<item>
<title>Adverse pregnancy outcomes, familial predisposition, and cardiovascular risk: a Swedish nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39916371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Sisters of women with APOs face a moderately increased risk of CVD, suggesting a genetic and/or environmental influence on the association between APOs and CVDs. These findings underscore the need for evaluating the effectiveness of targeted preventive measures in women with APOs and their sisters.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7:ehae889. doi: 10.1093/eurheartj/ehae889. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Adverse pregnancy outcomes (APOs) are recognized as significant female-specific risk factors for cardiovascular disease (CVD). A potential shared familial susceptibility between APOs and CVD has been proposed, but not thoroughly explored. This study employs a quasi-experimental family comparison design to investigate shared familial predisposition between APOs and CVD, by assessing risk of CVD in APO-exposed women and their APO-free sisters.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Nationwide population-based cohort study encompassing primiparous women, without prior CVD, with registered singleton births in the Swedish Medical Birth Register between 1992 and 2019, grouped into: women with ≥1 APO (165 628), APO-free sisters (60 769), and unrelated APO-free comparator women (992 108). All study participants were followed longitudinally, through linkage with national health registers, from delivery until 2021, for primary endpoint major adverse cardiac events, and its individual components: ischaemic heart disease, heart failure, and cerebrovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median follow-up of 14 years, APO-exposed women exhibited increased rates of CVDs compared with APO-free comparators. Adverse pregnancy outcome-free sisters exhibited elevated adjusted hazard ratios (aHRs) of major adverse cardiac event {aHR 1.39 [95% confidence interval (CI) 1.13-1.71]}, heart failure [aHR 1.65 (95% CI 1.14-2.39)], and cerebrovascular events [aHR 1.37 (1.04-1.72)] compared with the APO-free comparators, while no significant increase in ischaemic heart disease was observed. Within-family analysis revealed lower CVD rates in APO-free sisters compared with their APO-exposed counterparts, except for no significant difference in cerebrovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sisters of women with APOs face a moderately increased risk of CVD, suggesting a genetic and/or environmental influence on the association between APOs and CVDs. These findings underscore the need for evaluating the effectiveness of targeted preventive measures in women with APOs and their sisters.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39916371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39916371</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae889>10.1093/eurheartj/ehae889</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39916371</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Ängla Mantel</dc:creator>
<dc:creator>Charlotte Lindblad Wollmann</dc:creator>
<dc:creator>Jonas Faxén</dc:creator>
<dc:creator>Anna Sandström</dc:creator>
<dc:creator>Hanna Mühlrad</dc:creator>
<dc:creator>Olof Stephansson</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adverse pregnancy outcomes, familial predisposition, and cardiovascular risk: a Swedish nationwide study</dc:title>
<dc:identifier>pmid:39916371</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae889</dc:identifier>
</item>
<item>
<title>Brainstem neuropeptidergic neurons link a neurohumoral axis to satiation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39914383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>Hunger is evolutionarily hardwired to ensure that an animal has sufficient energy to survive and reproduce. Just as important as knowing when to start eating is knowing when to stop eating. Here, using spatially resolved single-cell phenotyping, we characterize a population of neuropeptidergic neurons in the brainstem's dorsal raphe nucleus (DRN) and describe how they regulate satiation. These neurons track food from sensory presentation through ingestion, integrate these signals with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 29:S0092-8674(25)00047-9. doi: 10.1016/j.cell.2025.01.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hunger is evolutionarily hardwired to ensure that an animal has sufficient energy to survive and reproduce. Just as important as knowing when to start eating is knowing when to stop eating. Here, using spatially resolved single-cell phenotyping, we characterize a population of neuropeptidergic neurons in the brainstem's dorsal raphe nucleus (DRN) and describe how they regulate satiation. These neurons track food from sensory presentation through ingestion, integrate these signals with slower-acting humoral cues, and express cholecystokinin (CCK). These CCK neurons bidirectionally regulate meal size, driving a sustained meal termination signal with a built-in delay. They are also well positioned to sense and respond to ingestion: they express a host of metabolic signaling factors and are integrated into an extended network known to regulate feeding. Together, this work demonstrates how DRN CCK neurons regulate satiation and identifies a likely conserved cellular mechanism that transforms diverse neurohumoral signals into a key behavioral output.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39914383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39914383</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.018>10.1016/j.cell.2025.01.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39914383</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Srikanta Chowdhury</dc:creator>
<dc:creator>Nachiket G Kamatkar</dc:creator>
<dc:creator>Wendy Xueyi Wang</dc:creator>
<dc:creator>Christa A Akerele</dc:creator>
<dc:creator>Jiahao Huang</dc:creator>
<dc:creator>Junlin Wu</dc:creator>
<dc:creator>Amajindi Nwankpa</dc:creator>
<dc:creator>Charlotte M Kane</dc:creator>
<dc:creator>Varun M Bhave</dc:creator>
<dc:creator>Hao Huang</dc:creator>
<dc:creator>Xiao Wang</dc:creator>
<dc:creator>Alexander R Nectow</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Brainstem neuropeptidergic neurons link a neurohumoral axis to satiation</dc:title>
<dc:identifier>pmid:39914383</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.018</dc:identifier>
</item>
<item>
<title>Engineered commensals for targeted nose-to-brain drug delivery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39914382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>Intranasal administration through the olfactory epithelium (OE) presents a direct pathway for brain-targeted therapeutic delivery, although its feasibility is hampered by the anatomical and absorptive limitations of the OE. In this study, we identified Lactobacillus plantarum WCFS1 (Lp), a commensal strain with a natural affinity for the OE and engineered it to function as a vector for cerebral drug delivery. Upon intranasal administration, Lp released specific payload molecules within the OE,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 3:S0092-8674(25)00046-7. doi: 10.1016/j.cell.2025.01.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Intranasal administration through the olfactory epithelium (OE) presents a direct pathway for brain-targeted therapeutic delivery, although its feasibility is hampered by the anatomical and absorptive limitations of the OE. In this study, we identified Lactobacillus plantarum WCFS1 (Lp), a commensal strain with a natural affinity for the OE and engineered it to function as a vector for cerebral drug delivery. Upon intranasal administration, Lp released specific payload molecules within the OE, with subsequent transport and accumulation in the brain. The therapeutic efficacy of Lp was further validated by the recombinant production and secretion of appetite-regulating hormones. When administered intranasally in a murine model of obesity prevention, the engineered Lp significantly alleviated obesity-related symptoms. This was evidenced by decreased appetite, reduced body weight gain, and improved glucose metabolism and fat mass deposition. Our study demonstrates the capability of Lp as an intranasal delivery vehicle, emphasizing its potential for brain-targeted therapeutic applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39914382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39914382</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.017>10.1016/j.cell.2025.01.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39914382</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Haosheng Shen</dc:creator>
<dc:creator>Nikhil Aggarwal</dc:creator>
<dc:creator>Beiming Cui</dc:creator>
<dc:creator>Guo Wei Foo</dc:creator>
<dc:creator>Yuanzhi He</dc:creator>
<dc:creator>Santosh Kumar Srivastava</dc:creator>
<dc:creator>Shengjie Li</dc:creator>
<dc:creator>Marcus Ze Xian Seah</dc:creator>
<dc:creator>Kwok Soon Wun</dc:creator>
<dc:creator>Hua Ling</dc:creator>
<dc:creator>In Young Hwang</dc:creator>
<dc:creator>Chun Loong Ho</dc:creator>
<dc:creator>Yung Seng Lee</dc:creator>
<dc:creator>Matthew Wook Chang</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineered commensals for targeted nose-to-brain drug delivery</dc:title>
<dc:identifier>pmid:39914382</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.017</dc:identifier>
</item>
<item>
<title>Oriental Congress of Cardiology in China: past, present, and future perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913255/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehae848. doi: 10.1093/eurheartj/ehae848. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913255/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39913255</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae848>10.1093/eurheartj/ehae848</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913255</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yiqing Hu</dc:creator>
<dc:creator>Hao Lu</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oriental Congress of Cardiology in China: past, present, and future perspectives</dc:title>
<dc:identifier>pmid:39913255</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae848</dc:identifier>
</item>
<item>
<title>The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehae833. doi: 10.1093/eurheartj/ehae833. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39913237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae833>10.1093/eurheartj/ehae833</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913237</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Anna Norhammar</dc:creator>
<dc:creator>Viveca Ritsinger</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed</dc:title>
<dc:identifier>pmid:39913237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae833</dc:identifier>
</item>
<item>
<title>Correction to: Erythritol and xylitol and cardiovascular disease risk: a growing concern</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehaf082. doi: 10.1093/eurheartj/ehaf082. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39913117</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf082>10.1093/eurheartj/ehaf082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913117</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Erythritol and xylitol and cardiovascular disease risk: a growing concern</dc:title>
<dc:identifier>pmid:39913117</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf082</dc:identifier>
</item>
<item>
<title>Correction to: Carotid artery atherosclerosis: mechanisms of instability and clinical implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207213747&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehaf085. doi: 10.1093/eurheartj/ehaf085. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207213747&v=2.18.0.post9+e462414">39913114</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf085>10.1093/eurheartj/ehaf085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913114</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Carotid artery atherosclerosis: mechanisms of instability and clinical implications</dc:title>
<dc:identifier>pmid:39913114</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf085</dc:identifier>
</item>





























</channel>
</rss>